Price Disclosure Reductions for 2020 October Cycle

This summary only includes medicines taking a price disclosure reduction on 1 October 2020. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes below show percentage (%) price differences and ex‑manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.

Flow-on Reductions for F2 Combination Items

Responsible persons with a brand of an F2 combination item should note that:

  • if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 October 2020 if the price of a component ingredient is also reduced and flowing this component price on results in a lower price; or
  • if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.

Outcomes for flow-on price disclosure reductions to F2 combination items were communicated to responsible persons with brands of affected drugs in July 2020.

Legal Determination & Next Steps

The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website.

Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their April 2020 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable and set out in the table below). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 31 March 2020 will also take the reduction on 1 October 2020 under section 99ADHA of the Act.

An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process.  The date for lodgement of disputes was 5pm AEST on 3 July 2020. 

Indicative prices for 1 October 2020 (including price to pharmacy, dispensed price for maximum quantity and price premiums) were published on 27 July 2020.

Final prices for 1 October 2020 (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from September 2020.

Excel version of 2020 October Cycle Outcomes Summary

2020 October Cycle Outcomes Summary

2020 October Cycle Outcomes Summary
      [Average AEMP minus WAPD = WADP] [Difference between April '20
AEMP & WADP = % Difference]		    
Legal Instrument Drug
(drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria)		 Legal Instrument MoA Legal Instrument Form Average
AEMP
($)		 WAPD
(%)
across a
drug/MoA		 WADP -
potential
October '20
PBS Price (AEMP)
($) per
pharmaceutical
item		 April '20
AEMP
($)		 Percentage difference between April '20 and October '20 PBS prices (AEMP) (%) per
pharmaceutical item		 Calculations based on:

OWAPD = all brand data

GWAPD = originator brand data removed for at least one pharmaceutical item

No originator brand determined

Does not meet 30 month clock		 Applicable Unadjusted Price Reduction
10% or 30%
acamprosate Oral Tablet (enteric coated) containing acamprosate calcium 333 mg 108.07 11.60% 95.53 108.07 11.60% Does not meet 30 month clock 10
aripiprazole Oral Tablet 10 mg 74.47 11.17% 57.33 64.54 11.17% GWAPD 10
aripiprazole Oral Tablet 15 mg 105.68 11.18% 81.35 91.59 11.18% GWAPD 10
aripiprazole Oral Tablet 20 mg 128.64 11.18% 99.03 111.49 11.18% GWAPD 10
aripiprazole Oral Tablet 30 mg 156.76 11.18% 120.67 135.86 11.18% GWAPD 10
azacitidine Injection Powder for injection 100 mg 217.64 13.72% 156.61 181.51 13.72% GWAPD 10
bosentan Oral Tablet 125 mg (as monohydrate) 1113.08 19.30% 898.26 1113.08 19.30% Does not meet 30 month clock 10
bosentan Oral Tablet 62.5 mg (as monohydrate) 1113.08 19.30% 898.26 1113.08 19.30% Does not meet 30 month clock 10
entecavir Oral Tablet 0.5 mg (as monohydrate) 144.49 40.20% 72.51 121.25 40.20% GWAPD 10
entecavir Oral Tablet 1 mg (as monohydrate) 234.98 40.20% 117.91 197.18 40.20% GWAPD 10
ezetimibe Oral Tablet 10 mg 20.86 27.62% 12.71 17.56 27.62% Does not meet 30 month clock 10
fenofibrate Oral Tablet 145 mg 18.39 16.97% 15.27 18.39 16.97% Does not meet 30 month clock 10
fenofibrate Oral Tablet 48 mg 12.26 16.97% 10.18 12.26 16.97% Does not meet 30 month clock 10
itraconazole Oral Capsule 100 mg 109.35 11.09% 97.22 109.35 11.09% GWAPD 10
itraconazole Oral Capsule 50 mg 109.35 11.09% 97.22 109.35 11.09% GWAPD 10
olmesartan with hydrochlorothiazide Oral Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg 5.75 13.28% 4.57 5.27 13.28% GWAPD 10
olmesartan with hydrochlorothiazide Oral Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg 10.65 11.60% 8.46 9.57 11.60% GWAPD 10
olmesartan with hydrochlorothiazide Oral Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg 12.04 13.00% 9.57 11.00 13.00% GWAPD 10
pegfilgrastim Injection Injection 6 mg in 0.6 mL single use pre-filled syringe 1175.00 20.43% 934.95 1175.00 20.43% GWAPD 10
pregabalin Oral Capsule 150 mg 24.02 23.31% 18.42 24.02 23.31% Does not meet 30 month clock 10
pregabalin Oral Capsule 25 mg 7.08 23.31% 5.43 7.08 23.31% Does not meet 30 month clock 10
pregabalin Oral Capsule 300 mg 35.84 23.33% 27.48 35.84 23.33% Does not meet 30 month clock 10
pregabalin Oral Capsule 75 mg 15.66 23.31% 12.01 15.66 23.31% Does not meet 30 month clock 10
rituximab* Injection Solution for I.V. infusion 100 mg in 10 mL 479.73 18.94% 388.87 479.73 18.94% Does not meet 30 month clock 10
rituximab* Injection Solution for I.V. infusion 500 mg in 50 mL 1199.32 18.94% 972.17 1199.32 18.94% Does not meet 30 month clock 10
rosuvastatin* Oral Tablet 10 mg (as calcium) 5.14 38.52% 3.16 5.14 38.52% GWAPD 30
tenofovir Oral Tablet containing tenofovir disoproxil fumarate 300 mg 339.37 11.93% 298.88 339.37 11.93% Does not meet 30 month clock 10
tenofovir Oral Tablet containing tenofovir disoproxil maleate 300 mg 339.37 11.93% 298.88 339.37 11.93% Does not meet 30 month clock 10
tenofovir Oral Tablet containing tenofovir disoproxil phosphate 291 mg 339.37 11.93% 298.88 339.37 11.93% Does not meet 30 month clock 10
teriflunomide Oral Tablet 14 mg 628.85 18.71% 511.19 628.85 18.71% Does not meet 30 month clock 10
tobramycin Injection Injection 80 mg (as sulfate) in 2 mL (without preservative) 23.00 11.87% 20.27 23.00 11.87% GWAPD 10
tobramycin Injection Injection 80 mg in 2 mL 21.00 11.86% 18.51 21.00 11.86% GWAPD 10
trastuzumab Injection Powder for I.V. infusion 150 mg 533.22 11.81% 470.25 533.22 11.81% Does not meet 30 month clock 10
trastuzumab Injection Powder for I.V. infusion 420 mg 1493.02 11.81% 1316.69 1493.02 11.81% Does not meet 30 month clock 10
trastuzumab Injection Powder for I.V. infusion 60 mg 213.29 11.81% 188.10 213.29 11.81% Does not meet 30 month clock 10
trastuzumab Injection Solution for subcutaneous injection containing trastuzumab 600 mg in 5 mL 1667.10 11.81% 1470.22 1667.10 11.81% Does not meet 30 month clock 10
zoledronic acid Injection Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL 132.37 38.31% 72.79 118.00 38.31% GWAPD 30
zoledronic acid Injection Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL 132.37 38.31% 72.79 118.00 38.31% GWAPD 30
zoledronic acid Injection Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL 177.21 38.31% 97.47 157.98 38.30% GWAPD 30

Confirmed prices of brands scheduled for a price disclosure reduction

The Confirmed Prices Report outlines the approved ex-manufacturer prices for brands scheduled to take a price disclosure reduction. The reports for the 2020 October cycle can be downloaded below.

Last updated
6 October 2020